Aimmune Therapeutics, Inc.

( )
AIMT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. -1.98%242.591.3%$854.07m
MRNAModerna, Inc. -2.27%67.160.0%$716.87m
IMMUImmunomedics, Inc. 0.14%85.1711.0%$669.53m
NVAXNovavax, Inc. -9.01%101.5796.5%$605.16m
GILDGilead Sciences, Inc. -0.49%63.091.0%$573.14m
ILMNIllumina, Inc. 1.67%273.003.5%$451.06m
REGNRegeneron Pharmaceuticals, Inc. -1.11%565.192.7%$438.62m
BIIBBiogen, Inc. -0.21%272.201.6%$337.47m
VRTXVertex Pharmaceuticals, Inc. -1.41%263.821.9%$321.90m
ALXNAlexion Pharmaceuticals, Inc. -1.82%112.432.0%$278.98m
SRNESorrento Therapeutics, Inc. -10.95%9.601.5%$268.90m
MNTAMomenta Pharmaceuticals, Inc. -0.13%52.293.0%$205.05m
VXRTVaxart, Inc. -17.83%7.190.0%$204.43m
SGENSeattle Genetics, Inc. -1.47%179.276.0%$202.41m
BMRNBioMarin Pharmaceutical, Inc. -1.17%78.434.3%$197.61m

Company Profile

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.